
Sarcoidosis is a multisystem disease characterized by non-caseating granuloma that affects the nervous system occasionally. When neurosarcoidosis infiltrate the pituitary gland leading to panhypopituitarism, result can be devastating. We present here a case of 30-year-old lady who presented with fever and headache for 6 months along with prolonged period of amenorrhea and forgetfulness. She also had increased thirst and polyuria. Her hormone profiles were suggestive of panhypopituitarism. MRI of brain showed a contrast enhancing lesion in the sellar and suprasellar region along with nodular leptomeningeal enhancement . We retrogradely searched for the underlying reason behin`d this .Her MT was 0 along with ground glass opacity in both lung fields in HRCT chest which made the diagnosis of neurosarcoidosis most likely. We treated her with prednisolone to manage neurosarcoidosis and secondary adrenal insufficiency along with sequential hormone replacement with desmopressin and levothyroxine . Follow up MRI of brain done 3 months later showed near complete resolution of lesion along with significant clinical improvement. J Dhaka Med Coll. 2024; 33(2) : 80-86
Background: Although the symptoms of coronavirus disease 2019 (COVID-19) are predominantly respiratory. Headache is one of the most frequent neurological symptoms. There is a wide variation in the prevalence of headaches, and little is known regarding the characteristics and outcomes of headaches in COVID-19 patients. So, this study aimed to determine the characteristics and headache outcomes among COVID-19 patients. Methods: This was a hospital-based prospective cohort study conducted in Dhaka Medical College Hospital from January 2021 to December 2021. Confirmed COVID-19 patients with Reverse Transcription Polymerase Chain Reaction (RT-PCR) were enrolled in the study. The severity of the headache was assessed by the Numerical Rating Scale (NRS, 0-10). All the patients with headaches were followed up by telephonic interviews in the 2nd week and at the end of the 4th week of the onset of the headache. For patients who experienced persistent headaches after 4th week, the impact of headaches on quality of life was assessed with the Headache Disability Index (HDI). Results: We included 362 patients in this study. The majority (52.5%) of the study population belonged to severe COVID-19 infection. Fever was the most common (63.81%) symptom among the study subjects. Headache was present in 19.06% of the patients. The mean (±SD) age of participants was 54(±14.7). Patients having headaches were younger 44.2±13.8 vs 56±13.8, p<0.05) than those have no headaches. Headache was more prevalent among the female (37[53.6%] vs 102[34.8%]). Tension-type headache (TTH) was the most common (60%) headache phenotype. The majority (68.12%) of the cases of headache occurred concomitantly with other COVID-19 symptoms. COVID-19-related headaches were, in most cases, bilateral, pressing, and of moderate intensity. Fever and pre-existing headaches were associated with significantly more frequency, duration, and intensity than COVID-19 headaches (p<0.05). Most patients (86.9%) recovered from headache within 4 weeks of onset. Median (IQR) recovery time was 10 (7.75) days. Nine patients (13.1%) did not recover from headaches in the 4th week of the survey. The Mean (±SD) HDI score was 24.4(±0.76) in patients who experienced headaches at the end of 4th week, which indicates mild disability. Conclusion: This study revealed that headache was present in about one-fifth of the hospitalized patients with COVID-19. Younger age and female gender were significantly associated with headaches. Most of the patients recovered within four weeks of the onset of headache. J Dhaka Med Coll. 2024; 33(1) : 18-26
Background: Non-compressive myelopathy (NCM) has a wide temporal and clinical profile with etiology that varies over different geographical locations. The etiology may vary according to age, sex, geographical location and other associated factors. There remains a great deal of heterogeneity in clinical features and imaging findings. The functional outcome also differ according to etiology, extent of involvement and rapidity of the management. Aims: To evaluate the clinical features and functional outcome of patients with non-compressive myelopathy. Methods: This observational study was carried out in the Department of Neurology, Neurosurgery and Medicine of Dhaka Medical College Hospital, Dhaka, during January2018 to December 2019. A total of 84 patients suffering from non-compressive myelopathy were included in this study. Age >18 years, both male and female patients with features of myelopathy admitted within 14 days of onset were enrolled in this study and followed up for 180 days. Results: 40 (47.5%) patients had acute transeverse myelitis (ATM) without spinal shock followed by 26(30.9%) had ATM with spinal shock, 9(10.8%) had multiple sclerosis (MS), 6(7.2%) had neuromyelitis optica (NMO) and 3(3.6%) had neuromyelitis optica specterum disorders (NMOSD). More than one third (38.2%) patients belonged to age 18-20 years followed by 22(26.3%) in 21- 30 years, 20 (23.9%) in 31-40 years, 6(7.2%) in 41-50 years and 4(4.8%) in >50 years. Male to female ratio was almost 2:1. Almost two third (63.1%) patients had paraplegia and 31(36.9%) had quadriplegia. Three fourth (75.0%) patients had sudden onset and 21(25.0%) had insidious onset. More than three fourth (84.5%) patients had sensory involvement. Two third (65.5%) patients had bowel and bladder involvement. The mean Modified Rankin Scale (MRS) score on admission was 4.3±0.86 and 3.13±1.15 at 180 days. The difference was statistically significant (p<0.05) between MRS score on admission and MRS score at 180 days. Almost half (48.0%) patients had improved MRS score, followed by 20(20.0%) static, 16(16.0%) worse. The mean barthel index was 34.35±16.71 and 50.06±19.75 on admission and at 180 days (p value <0.01). More than half (53.0%) patients had improved barthel index, followed by 22(22.0%) worse, 16(16.0%) lost to follow up and 9(9.0%) static. Conclusion: ATM was the most common diagnosis among non-compressive myelopathy; with the 2nd decade of the life being the most common age group and predominantly affecting male. Patients with non compressive myelopathy most commonly presented with paraplegia, sudden onset symptoms, sensory involvement, bowel and bladder dysfunction. More than half of the patient improved at day 180. J Dhaka Med Coll. 2023; 32(2) : 131-138
Background: Early prediction of GDM by measuring a biomarker at first trimester of pregnancy may prevent maternal and fetal complication. Adiponectin, which modulate insulin sensitivity, is secreted from adipose tissue and decreases blood glucose level. The objective of the study was to evaluate the association of maternal first trimester serum adiponectin with development of GDM. Methodology: This longitudinal study was conducted in the BSMMU, Dhaka from June, 2021 to May, 2022 where pregnant women of first trimester were selected by purposive convenient sampling. At first 94 pregnant women were selected after excluding diabetes or previous history of GDM and their serum adiponectin level was measured. Then the participants were followed up at 24-28 weeks of gestation and OGTT was done to detect GDM. ROC was used to decide the best cut-off point of adiponectin level for detection of GDM. The respondents were divided into ‘below cut-off’ group and ‘above cut-off’ group. Differences between two groups were assessed by statistical test. Results: A total 18 respondents developed GDM from both group. In below cut-off’ group, out of 26 respondents 13 developed GDM and remaining 13 were euglycemic. Whereas in above cut-off group, out of 62 respondents, majority 57 were euglycemic and only 5 women developed GDM. ROC analysis of adiponectin level for detection of GDM, a AUC value 0.887 (95% confidence interval 0.802-0.972) was found which was statistically significant (p<0.001). A cut off value of